Efficacy of Ustekinumab Intravenously q12 Weeks for Maintenance Therapy for Crohn's Disease.

Ustekinumab is a monoclonal antibody administered as a weight-based intravenous (IV) induction, followed by 90 mg subcutaneous injections every 8 weeks for the treatment of Crohn's disease. We report 6 patients who were administered IV ustekinumab every 12 weeks for maintenance therapy due to financial constraints in place of the standard dosing regimen. All patients tolerated IV ustekinumab, and no adverse events occurred to this point.

A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study.

Background: Advanced combination therapy with biologics and small molecules has seen more widespread implementation for inflammatory bowel disease (IBD). However, there is a paucity of data available to guide the successful de-escalation of combination therapy following the achievement of disease remission. Therefore, we pursued this retrospective study to evaluate our center's approach to de-escalation of these patients.

Primary Hepatic Neuroendocrine Tumor With Ectopic Adrenocorticotropic Hormone Production.

This report describes the case of a 63-year-old female with a metastatic neuroendocrine tumor (NET). Imaging studies revealed a primary hepatic NET (PHNET) originating in the porta hepatis and associated with extensive hepatic metastasis. This represents an extremely rare presentation of PHNET associated with ectopic adrenocorticotropic hormone (ACTH) production and hypercortisolism.

Thrombocytopenia with Absent Radii (TAR) Syndrome Without Significant Thrombocytopenia.

Thrombocytopenia with absent radii (TAR) syndrome is a rare genetic syndrome that occurs with a frequency of about 0.42 cases per 100,000 live births. It is characterized by hypo-megakaryocytic thrombocytopenia with bilateral absent radii and the presence of both thumbs.